Position in NVO
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$470,962
+$80,530 QoQ
Shares Held
9,824
-7.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#731
of 1,349 holders
Holding Since
Mar 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FLC Capital Advisors holds $21,615,806 across 11 Drug Manufacturers - General names. NVO ranks #8 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
86,579 | $11,125,401 | |
| 2 | JNJ |
Johnson & Johnson
|
13,403 | $3,403,959 | |
| 3 | PFE |
Pfizer Inc
|
66,092 | $1,591,495 | |
| 4 | ABBV |
AbbVie Inc.
|
6,063 | $1,525,693 | |
| 5 | LLY |
ELI LILLY & Co
|
1,111 | $1,332,566 | |
| 6 | AMGN |
Amgen Inc
|
2,086 | $755,382 | |
| 7 | NVS |
Novartis AG
|
3,066 | $480,503 | |
| 8 | NVO |
Novo Nordisk A S
This page
|
9,824 | $470,962 |
All Filings in NVO
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $470,962 | 9,824 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $390,432 | 10,624 | Shares | Sole | 2026-05-04 | |
| 2024-12-31 | $236,555 | 2,750 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $327,442 | 2,750 | Shares | Sole | 2024-10-16 | |
| 2024-06-30 | $392,535 | 2,750 | Shares | Sole | 2024-07-15 | |
| 2024-03-31 | $353,100 | 2,750 | Shares | Sole | 2024-05-06 | |
| 2023-12-31 | $284,487 | 2,750 | Shares | Sole | 2024-01-18 | |
| 2023-09-30 | $250,085 | 2,750 | Shares | Sole | 2024-01-18 | |
| 2023-06-30 | $222,516 | 1,375 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | $218,817 | 1,375 | Shares | Sole | 2023-04-27 | |
| No filing history on record for this holder in this stock. | ||||||